In this issue:
In this first edition of the ILC 2019 daily news we anticipate the arrival of delegates from around the world to discuss the latest advances at the frontline of hepatology. Read on for top tips on how to get the best out of ILC 2019 and what not to miss over the next few days.
What's in store at ILC
ILC 2019 continues to focus on excellence in cutting-edge research, with 246 original scientific presentations, 1,474 paper and electronic posters and 3 state-of-the-art lectures. There is also plenty of opportunity for interaction and education in our grand rounds, skills workshops, poster tours and brand new ‘Solve the case’ and ‘Pros and cons’ sessions.
- Meet the experts: from Thursday through Sunday, meet with some of the biggest names in hepatology in an interactive, face-to-face setting in 36 informal workshops.
- Breakfast morning rounds: enjoy a tea or coffee with invited experts and their junior colleagues during Friday and Sunday’s morning rounds – with 8 different clinical cases to choose from, there’s something to interest everyone!
- Solve the case: do you have a case or a patient that worries you or you’re not sure how to solve it? Bring it to the Hepatology Arena to discuss and take advice from major experts in the field.
- ILC 2019 is going live! Can’t decide which sessions to attend? No need to worry – livestreamed sessions will be available every day via the congress app and website.
- Join EASL Campus today! Discover the engaging and interactive educational resources available at EASL’s open-access eLearning platform.
- Taking a stand on the big public health issues in liver disease, EASL will unveil its Policy Statements on NAFLD, alcohol-related liver disease and hepatitis C elimination.
- Follow the EASL Journey in the Mall at the Congress centre and see how the society can be there for you through every stage in your career, including education and networking as a young investigator, opportunities to speak and disseminate your work as an experienced researcher and the collective influence to work towards policy changes that improve the lives of patients with liver disease.
‘ILC Daily News’ was supported by grants from: Bayer, Boehringer Ingelheim and Eisai